Innovent And HUTCHMED Jointly Announce NMPA Conditional Approval For TYVYT® (Sintilimab Injection) In Combination With ELUNATE® (Fruquintinib) For The Treatment Of Advanced Endometrial Cancer
Innovent And HUTCHMED Jointly Announce NMPA Conditional Approval For TYVYT® (Sintilimab Injection) In Combination With ELUNATE® (Fruquintinib) For The Treatment Of Advanced Endometrial Cancer . (MENAFN - PR Newswire) 
  
  
 
 
 
 
 
 SAN FRANCISCO, U.S. andSUZHOU, China, Dec. 3, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108953434/Innovent-And-HUTCHMED-Jointly-Announce-NMPA-Conditional-Approval-For-TYVYT-Sintilimab-Injection-In-Combination-With-ELUNATE-Fruquintinib-For-The-Treatment-Of-Advanced-Endometrial-Cancer
2024-12-03
rss
(MENAFN - PR Newswire) 
  
  
 
 
 
 
 
 SAN FRANCISCO, U.S. andSUZHOU, China, Dec. 3, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical ...
Innovent And HUTCHMED Jointly Announce NMPA Conditional Approval For TYVYT® (Sintilimab Injection) In Combination With ELUNATE® (Fruquintinib) For The Treatment Of Advanced Endometrial Cancer